Ipsen holds 2008 profit, but future not bright

9 March 2009

French drug firm Ipsen reported almost flat profit year-on-year for the  2008, but forecasts a difficult period ahead as European markets slow in  the global financial crisis.

Total revenues rose 5% to 1.04 billion euros ($1.33 billion), while R&D  expense was cut 1% to 182.9 million euros. Net income was 147.7 million  euros, or 1.75 euros per share, versus 150.6 million euros, or 1.79  euros per share.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight